Venture Capital
-
When Regulatory Conversations Quietly Rewrite the Strategy
Most MedTech strategies are not rewritten in board meetings. They are rewritten gradually, often almost invisibly, through conversations with regulators that at the time appear to be clarifications rather than decisions. This is not because regulators intend to shape company direction. It happens because evidence-based environments reveal reality step-by-step, and each clarification alters what the…
-
Why Boards Often Realise the Value of a CMO Too Late
Clinical leadership in MedTech is rarely treated as a strategic variable at the start. In early stages, it often appears procedural. A role associated with compliance, trials, and regulatory navigation. Certainly treated as important but not always central to valuation. That perception tends to change when the inevitable pressure mounts. As scale approaches, clinical judgement…
Harun Rabbani 